RecruitingPhase 3NCT03295383
Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid
Studying Bullous pemphigoid
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospital, Rouen
- Principal Investigator
- Pascal JOLY, PrUniversity Hospital, Rouen
- Intervention
- Rituximab 1g IV(drug)
- Enrollment
- 130 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2019 – 2027
Study locations (27)
- CHU Amiens, Amiens, France
- CHU Angers, Angers, France
- CH Argenteuil, Argenteuil, France
- CHU Bordeaux, Bordeaux, France
- Brest University Hospital, Brest, France
- CHU Caen, Caen, France
- CHU Clermont Ferrand, Clermont-Ferrand, France
- CHU Dijon, Dijon, France
- CH Le Mans, Le Mans, France
- CHU Lille, Lille, France
- CHU de Limoges, Limoges, France
- HCL, Lyon, France
- APHM La Timone, Marseille, France
- CHU Montpellier, Montpellier, France
- CHU Nantes, Nantes, France
- +12 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03295383 on ClinicalTrials.govOther trials for Bullous pemphigoid
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06291350Peridontal and Intestinal Microbiota in Patients With Gingival Scarring PemphigoidCentre Hospitalier Universitaire de Nice
- RECRUITINGNANCT06479018Deciphering IL-17-dependant Inflammatory Response in Bullous PemphigoidCHU de Reims
- RECRUITINGNCT04198740Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular SurfaceCentre hospitalier de l'Université de Montréal (CHUM)